Altheia Science Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 4

Altheia Science General Information

Description

Developer of cell and gene therapeutics designed for the treatment of autoimmune diseases and liquid tumours. The company focuses on modulating the expression of PD-L1 on patients' hematopoietic stem and progenitor cells, restoring their therapeutic immune ability and eliminating autoreactive T lymphocytes along with novel tumor-specific antigens for CAR-T cells, enabling healthcare organizations to target the elimination of leukemic cells while sparing healthy ones.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Via Conservatorio, 30
  • 20122 Milan
  • Italy
+39 02
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • Via Conservatorio, 30
  • 20122 Milan
  • Italy
+39 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Altheia Science Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 31-Mar-2025 Completed Generating Revenue
2. Early Stage VC (Series A) 19-Dec-2018 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2017 Completed Pre-Clinical Trials
To view Altheia Science’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Altheia Science Patents

Altheia Science Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023194501-A1 Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens Inactive 05-Apr-2022
CA-3216175-A1 Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens Pending 05-Apr-2021
WO-2022214499-A3 Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens Inactive 05-Apr-2021
WO-2022214499-A9 Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens Inactive 05-Apr-2021
WO-2022214499-A2 Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigenscross-reference to related applications Inactive 05-Apr-2021 C07K16/2896
To view Altheia Science’s complete patent history, request access »

Altheia Science Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Altheia Science Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advanced Accelerator Applications Corporation Minority
Fin Posillipo Corporation Minority
Rottapharm Biotech Corporation Minority
Università degli Studi di Milano Statale University
To view Altheia Science’s complete investors history, request access »

Altheia Science FAQs

  • When was Altheia Science founded?

    Altheia Science was founded in 2017.

  • Where is Altheia Science headquartered?

    Altheia Science is headquartered in Milan, Italy.

  • What is the size of Altheia Science?

    Altheia Science has 6 total employees.

  • What industry is Altheia Science in?

    Altheia Science’s primary industry is Biotechnology.

  • Is Altheia Science a private or public company?

    Altheia Science is a Private company.

  • What is Altheia Science’s current revenue?

    The current revenue for Altheia Science is .

  • How much funding has Altheia Science raised over time?

    Altheia Science has raised $19.3M.

  • Who are Altheia Science’s investors?

    Advanced Accelerator Applications, Fin Posillipo, Rottapharm Biotech, and Università degli Studi di Milano Statale have invested in Altheia Science.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process